KarXT (xanomeline-trospium)

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

Authors: Colin Sauder, Luke A Allen, Elizabeth Baker, Andrew C Miller, Steven M Paul, Stephen K Brannan

Journal: Translational Psychiatry

Year Published: 2022

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline-trospium) on cognition in schizophrenia from the 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 […]

Back to Publications